Look out…the new CMI templates are finally here
TGA’s updated CMI templates and guidance is finally live on their website!
No new or additional content is required in the new templates. The intent was to revise the format to promote safe and effective use by improving the ease of identification and comprehension of information.
- Introduction of an easy to understand, one-page CMI summary for critical information about the safe and effective use of the medicine. This is optional for Non-Prescription (OTC) medicines or for any medicines where the CMI is enclosed as a pack insert.
- Separate templates for Prescription and Non-Prescription medicines, with the notable difference of having the summary page optional for the latter.
- Presentation of side effects in tabular format, categorised into Less serious/Common and Serious/Rare, with side effects grouped by their effect on the body (e.g. bleeding related) and what to do for each type of side effect. This new format helps patients quickly identify serious side effects requiring immediate action.
- Listing of active ingredient, excipients and potential allergens in a table for easy scanning.
- Reference to the use of external hyperlinks (e.g. instructional videos / diagrams for device use) to enhance understanding.
When do I need to implement the new templates by?
The new templates take effect from 1 January 2021 for newly registered medicines. All previously registered medicines must be in the revised format by 30 December 2025.
Ready to download the updated templates? Click here.
We offer deep support for navigating international regulatory processes. Whether it’s a TGA application, a strategy for MDR transition, a US presubmission or 510(k) filing, or specific help with regulatory documents (e.g. Clinical Evaluation Reports), or an update of your quality system to gain MDSAP. We understand you need a commercial approach which delivers viable options. Contact us to discuss your needs and how we can help. You can drop us an email [email protected] or call 1 888-271-5063 (US toll free) ♦ +61 2 9906 2984 (Sydney)
The views and options expressed in this article are those of the author/s and do not necessarily reflect the views of Brandwood CKC Pty Ltd ACN 128 762 505.
The information presented in this article is of a general nature only and does not consider the particular circumstances of your business. Prior results and case studies do not guarantee a similar outcome in future. You should not rely on this information, and you should seek specific advice for your particular business needs.
Where indicated, certain content has been sourced from third parties; we have not independently verified it. Neither Brandwood CKC nor the author makes any warranty as to the accuracy, completeness or reliability of this article, nor do those parties accept any liability or responsibility arising in any way from omissions or errors contained in the content.